CN104825478B - A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis - Google Patents
A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis Download PDFInfo
- Publication number
- CN104825478B CN104825478B CN201510174293.XA CN201510174293A CN104825478B CN 104825478 B CN104825478 B CN 104825478B CN 201510174293 A CN201510174293 A CN 201510174293A CN 104825478 B CN104825478 B CN 104825478B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- treat
- cow
- cow endometritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for being used to treat cow endometritis, prepared by following components in parts by weight：Tanshinone IIA4~8 parts, 3~5 parts of forsythin, 1~2 part of stachydrine hydrochloride, and there is provided its preparation method.Beneficial effects of the present invention are：Uterine perfusion agent is made in this 3 kinds of medicines, with antibacterial anti-inflammatory, the effect for promoting uterine contractile and uterus function to recover, treatment cow endometritis is evident in efficacy, and cure rate is efficient up to more than 90% up to more than 87%.The pharmaceutical composition is nonirritant to mucous membrane to animal safety, the problems such as can avoiding antibiotic residue and drug resistance, and environmental protection.
Description
Technical field
The present invention relates to veterinary drug preparation field, and in particular to a kind of pharmaceutical composition for being used to treat cow endometritis
And its preparation method of perfusion liquid.
Background technology
Cow endometritis is the inflammation for betiding cow uteri inner membrance, is a kind of milk cow postpartum common reproductive organs
Disease, is also the one of the main reasons for causing milk cow infertile.Endometritis often causes Uterine And Cervical Involution In The Cow to postpone, follicular development
And dysfunction, reproductive capacity decline, calving interval prolongation, Repeat breeding, output of milk decline, cause medical expense and mortality to increase
Plus, economic benefit reduction causes serious economic loss to milk cow production.China's cow endometritis the incidence of disease about
For 20%~50%.Milk cow postpartum reproductive diseases are accounted in the economic loss caused by German cow endometritis and vaginitis
50%, the U.S. is annual because barrenness of milk cow loss is up to 2.5 hundred million dollars, and 60%-95% infertility is caused by endometritis
's.It is estimated that the milk cow of every infection endometritis is 106 dollars in lactation period average cost, milk cow suffers from uterus in postpartum
Economic loss caused by after disease is up to 285 dollars/head；Shown according to research, milk cow suffers from after endometritis, the meeting of calving pen phase
Extension even 2 months 2 weeks, it is estimated that every daily economic loss of cow head is about 2.5-5.4 dollars, if according to average calving
Interval prolongation is calculated for 1 month, and the economic loss per cow head is 75-162 dollars.It can be seen that, the warp that cow endometritis is caused
Ji loss is very huge.At present, the treatment method of endometritis has local treatment, constitutional treatment and biological therapy, treatment
Medicine mainly has antibiotic, hormone, antiseptic and disinfectant drug and Chinese herbal medicine, and these medicines have certain treatment to cow endometritis
Effect, but also have many shortcomings.Antibiotic and hormone play huge effect in terms of cow endometritis is prevented and treated, but with
The extension of its application time, not only occurs in that toxic side effect and drug resistance, causes milk cow reproductive endocrine disorders, Er Qieyi
In Residues in Milk, curative effect reduction, or even cause to abandon milk or the valency sale of reduction milk, the strong of the mankind can be also endangered when remaining serious
Health.Chinese medicine is increasingly favored with its efficient, low toxicity, low-residual and the advantages of being not likely to produce drug resistance by domestic and foreign scholars.
Cow endometritis can be not only prevented and treated using Chinese medicine, and its adjustment effect to body can be played, it is to avoid antibiotic
The problems such as residual and drug resistance, and environmental protection.
The content of the invention
The purpose of the present invention can not only prevent and treat milk cow aiming at above-mentioned defect of the prior art there is provided a kind of
Endometrium is scorching, can also play its adjustment effect to body, it is to avoid the problems such as antibiotic residue and drug resistance, and environmental protection
Pharmaceutical composition for treating cow endometritis.
To achieve these goals, the technical scheme that provides of the present invention is：It is a kind of to be used to treat cow endometritis
Pharmaceutical composition, is prepared by following components in parts by weight：Tanshinone IIA4~8 parts, forsythin 3~5
Part, 1~2 part of stachydrine hydrochloride.
Further, a kind of above-mentioned pharmaceutical composition for being used to treat cow endometritis, is by according to parts by weight
What the following components of meter was prepared：Tanshinone IIA6 parts, 3 parts of forsythin, 1 part of stachydrine hydrochloride.
Second object of the present invention there is provided a kind of pharmaceutical composition perfusion for being used to treat cow endometritis
The preparation method of liquid, comprises the following steps：
1）According to above-mentioned proportioning, Tanshinone II is weighedA40~80g, 30~50g of forsythin, stachydrine hydrochloride 10~
20g, is ground into fine powder, mixes, obtains hybrid medicine powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly,
Room temperature is cooled to, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to
10000mL, is sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min, obtains pharmaceutical composition perfusion liquid.
Further, above-mentioned a kind of preparation side for being used to treat the pharmaceutical composition perfusion liquid of cow endometritis
Method, comprises the following steps：
1）According to above-mentioned proportioning, Tanshinone II is weighedA60g, forsythin 30g, stachydrine hydrochloride 10g, are ground into thin
Powder, mixes, obtains hybrid medicine powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly,
Room temperature is cooled to, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to
10000mL, is sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min, obtains pharmaceutical composition perfusion liquid.
Safety detection：
In order to determine the acute toxicity of Mouse oral trial drug, foundation is provided for data for clinical drug use.By improvement Kou Shi
Method design carries out trial test, determines median lethal dose（LD50）, as a result mouse all survivals, fail to find out minimal lethal dose, nothing
Method measures LD50, therefore maximum dosage-feeding method is used, 40 mouse are randomly divided into 2 groups, every group 20, respectively test group and right
According to group, test group is pressed per 1kg body weight 80ml pharmaceutical composition gavages, and control group presses 1kg body weight 80mL physiological saline gavages, divides 2
Secondary to gavage, Continuous Observation 7d after administration determines its maximum dosage-feeding on the 1st, determines the acute toxicity of trial drug.As a result it is heavy dose of
The administration same day, test group mouse spirit is depressed, and feeding, drinking-water and autonomic activities are reduced, and the sleeping ground of some mouse does not rise, and moves time step
State is unstable, and administration next day gradually recovers normal.Continuous Observation 7d, all mouse hairs are glossy, feeding, movable normal, nothing
Dead mouse.During off-test, the subcutaneous, heart, liver, spleen, lung, kidney and stomach and intestine are visually observed after test group and control group mice dissection
The organs such as road are without substantially observing anomalous variation.Show that what trial drug will not cause parenchymal viscera observes pathology damage.Mouse
Maximum dosage-feeding on the 1st of oral test medicine is 80ml/kg, equivalent to clinical milk cow（500kg）400 times of consumption per day, show
Trial drug is safer.
In order to investigate excitant and local toxicity of the medicine to mucous membrane, rabbit the irritating experiment with eyes and vagina thorn have been carried out
Swash property experiment.Eye irritation, experiment 5 healthy rabbits of selection, gives the intracapsular instillation physiology salt of experimental rabbits conjunctiva of left eye daily
Water, the intracapsular instillation decoction of conjunctiva of right eye, each 0.1mL makes rabbit eyes closed 8-10s, continuous eye drip 7d with hand, in each drop
At the moment and first after eye drip 6h observed and recordeds eyes local reaction situation, whether main detection rabbit cornea of both eyes muddy, rainbow
Film whether there is congested, bleeding and swelling, and pupil has reactionless to light, and conjunctiva whether there is congested, oedema and flow point secretion etc., is discontinued follow-up
Continuous observation 7d, reacts standards of grading corneal, iris and conjunctiva by Eye irritation and is scored respectively, average value is calculated, to same
The right and left eyes scoring of rabbit is compared, and is determined by eye irritation evaluation criterion.As a result show, after trial drug eye drip,
Eye observation index and control group no significant difference, show the medicine to rabbit eye irritation.
The irritation test of vaginal mucosa.Rabbit 10 is taken, female is randomly divided into test group and control group, every group 5,
Test group flexible pipe gently injects 1mL decoctions in rabbit vagina, keeps rabbit to lie on the back 5min, makes decoction abundant with vaginal mucosa
Contact；Control group irrigates physiological saline with method.Put to death after successive administration 7d, last dose 24h, take out vagina tissue, observation is glutinous
Film whether there is the phenomenons such as hyperemia, redness, and by vagina tissue, fixed, paraffin section, HE dyeing in 10% formalin, carry out pathology
Histological examination.As a result compared with control group, test group vaginal mucosa is smooth, does not occur the anomalies such as hyperemia, redness, cloudy
Road tissue carries out paraffin section inspection, and mucous membrane tissue is complete, change without exception.Show that trial drug is nonirritant to mucous membrane,
Mucosal drug delivery safety.
Beneficial effects of the present invention are：
It is a kind of for treating in pharmaceutical composition of cow endometritis and preparation method thereof that the present invention is provided, the red sage root
Ketone IIAThere are inhibitory action, the reparation also with anti-inflammatory and promotion organization to bacteriums such as staphylococcus, Escherichia coli, proteus
With palingenesis；Stachydrine hydrochloride has the effect of antibacterial and excited uterine smooth muscle；Forsythin is to Escherichia coli, grape ball
Bacterium, streptococcus have inhibitory action, also with antiinflammatory action；Uterine perfusion agent is made in this 3 kinds of medicines, with antibacterial anti-inflammatory, is promoted
Enter the effect that uterine contractile and uterus function recover, treatment cow endometritis is evident in efficacy, and cure rate has up to more than 87%
Efficiency is up to more than 90%.The pharmaceutical composition is nonirritant to mucous membrane to animal safety, can avoid antibiotic residue and drug resistance
The problems such as, and environmental protection.
Embodiment
Embodiment 1：
A kind of preparation method for being used to treat the pharmaceutical composition perfusion liquid of cow endometritis, comprises the following steps：
1）Weigh Tanshinone IIA40g, forsythin 40g, stachydrine hydrochloride 20g, are ground into fine powder, mix, are mixed
Medicine powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly,
Room temperature is cooled to, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to
10000mL, is sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min, obtains pharmaceutical composition.
Embodiment 2：
A kind of preparation method for being used to treat the pharmaceutical composition perfusion liquid of cow endometritis, comprises the following steps：
1）Weigh Tanshinone IIA80g, forsythin 15g, stachydrine hydrochloride 5g, are ground into fine powder, mix, and obtain mixing medicine
Thing powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly,
Room temperature is cooled to, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to
10000mL, is sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min, obtains pharmaceutical composition.
Embodiment 3：
A kind of preparation method for being used to treat the pharmaceutical composition perfusion liquid of cow endometritis, comprises the following steps：
1）Weigh Tanshinone IIA60g, forsythin 30g, stachydrine hydrochloride 10g, are ground into fine powder, mix, are mixed
Medicine powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly,
Room temperature is cooled to, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to
10000mL, is sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min, obtains pharmaceutical composition.
Embodiment 4：
Practical application is carried out using embodiment 3：
In July, 2012 breeds demonstration centre milk in December, 2013 in Lanzhou area just outside a city gate cattle farm, Gansu holstein cow
4 cattle farms such as cattle farm, Gansu Qin Wangchuan cattle farms, the small western ox cultivation Co., Ltd of Wuzhong City carry out treatment cow uteri inner membrance
Scorching clinical test.Suffer from endometritis milk cow and discharge sticky or viscous purulence rheuminess thing from vaginal orifice, hogback, exert duty and repeatly
Urination posture is done, root of the tail and perineum are contaminated, and discharge rate increases when lying prone sleeping.Though discharge rheuminess thing is had not seen sometimes,
But pus, purulence block or purulence wadding are mixed with during heat in mucus.Sometimes ill milk cow is out of heat or the oestrous cycle is irregular.Severe patient is suffered from
Sick Contents in Cows temperature rise, spirit is depressed, poor appetite, ruminates decrease, milk yield reduction.The reaction of examination per rectum uterine contractile subtracts
Weak, cornua uteri, corpus uteri increase in various degree, the uterine wall became uneven and soft or hard degree of quality is inconsistent.Pass through clinical examination
368 are made a definite diagnosis with examination per rectum, test group is randomly divided into（264）And control group（104）, every cattle uterus perfusion of test group
100ml, every cattle uterus of control group perfusion 50ml terramycin, the next day once, 4 times are a course for the treatment of, treat 1 course for the treatment of.As a result try
A group healing 230 is tested, cure rate is 87.12%, and invalid 24, total effective rate is 90.91%, control group cures 83, cure rate
For 79.81%, invalid 12, total effective rate is 88.46%, it is seen that the cure rate and total effective rate of test group are all higher than control group,
This explanation trial drug is evident in efficacy to cow endometritis.
Finally it should be noted that：The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention,
Although the present invention is described in detail with reference to the foregoing embodiments, for those skilled in the art, it still may be used
To be modified to the technical scheme described in foregoing embodiments, or equivalent substitution is carried out to which part technical characteristic.
Within the spirit and principles of the invention, any modification, equivalent substitution and improvements made etc., should be included in the present invention's
Within protection domain.
Claims (4)
1. a kind of be used to treat the pharmaceutical composition of cow endometritis, it is characterised in that be by parts by weight with
What lower component was prepared：Tanshinone IIA4~8 parts, 3~5 parts of forsythin, 1~2 part of stachydrine hydrochloride.
2. a kind of pharmaceutical composition for being used to treat cow endometritis according to claim 1, it is characterised in that be
Prepared by following components in parts by weight：Tanshinone IIA6 parts, 3 parts of forsythin, 1 part of stachydrine hydrochloride.
3. a kind of preparation method for being used to treat the pharmaceutical composition perfusion liquid of cow endometritis, it is characterised in that including
Following steps：
1）According to the proportioning described in claim 1, Tanshinone II is weighedA40~80g, 30~50g of forsythin, stachydrine hydrochloride 10
~20g, is ground into fine powder, mixes, obtains hybrid medicine powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly, cooled down
To room temperature, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to 10000mL, point
Loaded in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min obtain pharmaceutical composition perfusion liquid.
4. a kind of preparation method for being used to treat the pharmaceutical composition perfusion liquid of cow endometritis, it is characterised in that including
Following steps：
1）According to the proportioning described in claim 2, Tanshinone II is weighedA60g, forsythin 30g, stachydrine hydrochloride 10g, are ground into
Fine powder, mixes, obtains hybrid medicine powder；
2）In step 1）In obtained hybrid medicine powder, polyethylene glycol -200 8000mL, 60 DEG C of water-bath 2h are added, are stirred evenly, cooled down
To room temperature, 20min is centrifuged with 4000r/min, polyethylene glycol -200 is added after supernatant is merged and is settled to 10000mL, point
Loaded in Brown Glass Brown glass bottles and jars only, 100mL/ bottles, 100 DEG C of sterilizing 30min obtain pharmaceutical composition perfusion liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510174293.XA CN104825478B (en) | 2015-04-14 | 2015-04-14 | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510174293.XA CN104825478B (en) | 2015-04-14 | 2015-04-14 | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104825478A CN104825478A (en) | 2015-08-12 |
| CN104825478B true CN104825478B (en) | 2017-08-29 |
Family
ID=53803935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510174293.XA Expired - Fee Related CN104825478B (en) | 2015-04-14 | 2015-04-14 | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104825478B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650950A (en) * | 2004-12-16 | 2005-08-10 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine for treating cow endo metritis |
| CN102552366A (en) * | 2012-02-14 | 2012-07-11 | 江西正邦动物保健品有限公司 | Chinese medicinal extract composition as female livestock uterus cleaning liquid |
-
2015
- 2015-04-14 CN CN201510174293.XA patent/CN104825478B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650950A (en) * | 2004-12-16 | 2005-08-10 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine for treating cow endo metritis |
| CN102552366A (en) * | 2012-02-14 | 2012-07-11 | 江西正邦动物保健品有限公司 | Chinese medicinal extract composition as female livestock uterus cleaning liquid |
Non-Patent Citations (5)
| Title |
|---|
| HPLC法测定中药"清宫液2号"隐丹参酮和丹参酮ⅡA的含量;郭文柱 等;《中兽医医药杂志》;20071231(第3期);28-30 * |
| 中草药防治奶牛子宫内膜炎的现状及其药理作用机制;严作廷 等;《中国草食动物》;20111231;第31卷(第2期);54-57 * |
| 中药治疗牛子宫内膜炎的系统评价和Meta分析;董书伟 等;《畜牧兽医学报》;20151110;第46卷(第11期);2085-2096 * |
| 河北道地药材连翘的高效液相色谱指纹图谱研究;崔洋 等;《中草药》;20100228;第41卷(第2期);297-301 * |
| 盐酸益母草碱和盐酸水苏碱对大鼠离体子宫收缩的影响;秦美蓉 等;《今日药学》;20130731;第23卷(第07期);410-412 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104825478A (en) | 2015-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106466454A (en) | A kind of prevention and the gel for the treatment of gynecological inflammation | |
| Cui et al. | Efficacy of herbal tincture as treatment option for retained placenta in dairy cows | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN100493600C (en) | Pharmaceutical composition for preventing and curing endometritis and retained afterbirth disease of milk cow | |
| CN104721418B (en) | It is a kind of to be used to treat pharmaceutical composition of gynaecological imflammation and preparation method thereof and purposes | |
| CN101897758A (en) | Traditional Chinese medicinal composition for curing animal womb inflammation and other postpartum diseases | |
| CN104288222A (en) | Nano-medicine for treating dairy cow endometritis and preparation method of nano-medicine | |
| CN102240260B (en) | Medicament for treating colpoxerosis and preparation method thereof | |
| CN1255135C (en) | Chinese traditional medicine perfusate for preventing and treating female livestock barrenness | |
| CN110393768A (en) | A kind of combined traditional Chinese medicine dabbling drug of Gilt Uterus anti-inflammatory and its preparation method and application | |
| CN102846725A (en) | Compound povidone iodine suppository and preparation method and application thereof | |
| CN104825478B (en) | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis | |
| Cui et al. | Prophylactic strategy with herbal remedy to reduce puerperal metritis risk in dairy cows: A randomized clinical trial | |
| CN110507736B (en) | A Chinese medicinal perfusate for treating endometritis of female animal, and its preparation method | |
| CN104306909B (en) | Prevent and treat Chinese medicine composition of cattle uterus subinvolution and preparation method thereof | |
| CN101972451B (en) | Compound infusion preparation of Chinese herbal medicines and western medicines for treating cow hysteritis and preparation method thereof | |
| CN1268355C (en) | Traditional Chinese medicine for treating cow endo metritis | |
| CN104784311B (en) | Composition of medicine for preventing and treating animal aphtha hoof Huang and preparation method thereof | |
| CN104208194B (en) | Traditional Chinese medicine composition for treating bovine endometritis, preparation method and application thereof | |
| CN102552605B (en) | Tibetan veterinary medicament for detoxifying and removing necrotic tissues | |
| CN105193934B (en) | Compound essential oil for treating livestock endometritis and preparation method thereof | |
| CN112426436A (en) | Endometrium lotion and its application in treating endometritis | |
| CN105106431A (en) | Traditional Chinese medicine perfusion agent for treating cow ovarian quiescence and persistent corpus luteum infertility and preparation method thereof | |
| CN105998220A (en) | Traditional Chinese veterinary material medicine for treating endometritis of cows as well as preparation method and use of traditional Chinese veterinary material medicine | |
| CN105287763B (en) | A kind of Chinese medicine composition and its formulation method can be used for preventing and treating cow endometritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170829 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |